Balanced Risk-Reward Amid Evolving Growth Profile and Rising Competition at BioMarin

William Blair analyst Sami Corwin has maintained their neutral stance on BMRN stock, giving a Hold rating on February 17.

Sami Corwin has given his Hold rating due to a combination of factors tied to BioMarin’s changing growth profile and competitive landscape. While the company’s 2026 revenue outlook initially appears muted, he expects the inclusion of Amicus’s commercial portfolio after deal closure to materially improve the growth trajectory, given those assets’ meaningful 2025 sales contribution.

At the same time, Corwin views the slower Voxzogo growth outlook as a key risk, reflecting anticipated share pressure from Ascendis’s TransCon CNP and a potential oral achondroplasia therapy from BridgeBio. With Voxzogo likely to face mounting competition over the next two years and requiring further business development to fully offset that erosion, he sees a balanced risk‑reward profile that supports maintaining a Hold rather than a more decisive rating change.

According to TipRanks, Corwin is a 5-star analyst with an average return of 15.3% and a 52.79% success rate. Corwin covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Cabaletta Bio, and Beam Therapeutics.

In another report released on February 17, H.C. Wainwright also reiterated a Hold rating on the stock with a $60.00 price target.